"Preliminary results from Phase I/II open label clinical trials, which included both SCLC and carcinoid cancer patients, found that the majority of patients responded to NTX-010 treatment, with one patient exhibiting a 50 percent reduction in tumor size," observes Symank.
Traditionally, for SCLC, chemotherapy dosing is usually given every day for three days, with the cycle repeated every 21 days. The combination of cisplatin and etoposide is inconveniently administered through an IV infusion.
Comparatively, NTX-010 requires only one systemic dose because it can replicate itself and expand within the tumor by making thousands of copies of itself from one virus particle, each capable of infecting a new tumor cell and repeating the process. The convenience of once-only dosing ensures greater patient compliance, and improves their quality of life.
"Moreover, NTX-010 has not been found to have any drug-related serious side effects or dose limiting toxicities," observes Symank. "The highly selective and targeted nature of the product kills only the cancer cells, leaving the healthy cells undamaged."
Each year, Frost & Sullivan presents this award to the company that has demonstrated excellence in new products and technologies within its industry. The recipient company has shown innovation by launching a broad line of emerging products and technologies.
Frost & Sullivan's Best Practices Awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement
|SOURCE Frost & Sullivan|
Copyright©2009 PR Newswire.
All rights reserved